Arbutus Biopharma Corp (ABUS) is Downgraded by Chardan Capital Markets to Sell, Lowers Price Target to $ 2.75

Arbutus Biopharma Corp (ABUS) was Downgraded by Chardan Capital Markets to ” Sell” while Lowering the Price Target of the company shares to $ 2.75 from a previous price target of $3.25 . Earlier the firm had a rating of “Neutral ” on the company shares. Chardan Capital Markets advised their investors in a research report released on Jul 8, 2016.

Many Wall Street Analysts have commented on Arbutus Biopharma Corp. Chardan Capital Markets Upgraded Arbutus Biopharma Corp on Jun 16, 2016 to ” Neutral”, Price Target of the shares are set at $3.25.Chardan Capital Markets Initiated Arbutus Biopharma Corp on May 16, 2016 to “Sell”, Price Target of the shares are set at $3.25.

In a different news, on Aug 26, 2015, Richard C Jr Henriques (director) purchased 1,000 shares at $6.95 per share price.

Arbutus Biopharma Corp formerly Tekmira Pharmaceuticals Corporation is a Canada-based biopharmaceutical company focused on discovering developing and commercializing a cure for patients suffering from chronic hepatitis B infection a disease of the liver caused by hepatitis B virus (HBV). The Company seeks to effect a cure by targeting the three pillars necessary to develop a curative regimen for HBV. This includes suppressing HBV replication within liver cells stimulating and reactivating the body’s immune system so that it can mount an effective defense against the virus and eliminating the reservoir of viral genomic material known as covalently closed circular DNA or cccDNA that is the source of HBV persistence.

Arbutus Biopharma Corp

Leave a Reply

Arbutus Biopharma Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Arbutus Biopharma Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.